Investors Urged to Join Class Action Against ADMA Biologics Over Potential Securities Violations
In recent developments, Levi & Korsinsky, LLP has raised an alarm for investors of ADMA Biologics, Inc. (NASDAQ: ADMA), urging those who experienced financial losses to consider participating in a class action lawsuit. This situation arises from a series of alleged misleading financial disclosures made by the company between August 2024 and March 2026. During this period, ADMA Biologics purportedly filed multiple SEC reports that allegedly contained false certifications regarding their internal controls and omitted critical information regarding related party transactions. The financial integrity of a company is fundamental not only for its stakeholders but also for maintaining market confidence, and the allegations against ADMA Biologics may have far-reaching implications.
The controversy began when ADMA released its quarterly report for Q2 2024, where it disclosed purchases from GenesisBPS while neglecting to mention sales to Genesis BioPharma Services, an affiliated entity. This pattern of omission apparently continued in subsequent filings. Researchers have pointed out that while the company's reported revenues significantly surged from $92.6 million in 2023 to an impressive $362.5 million in 2025, these figures might have been artificially inflated due to a practice known as channel stuffing. Such a practice can significantly misrepresent a company’s financial health and mislead investors.
Culper Research, a company conducting independent investigations, published findings suggesting that ADMA’s reported growth was, in fact, a fabrication. They posited that absent channel stuffing, the revenue figures would illustrate a stark decline instead of the purported growth, raising substantial concerns about the accuracy of ADMA's financial statements. According to the allegations, the growth that ADMA claimed due to successful ASCENIV product sales was deceitful, with the real figures reflecting a 3% decline in revenues.
Investors who acquired shares of ADMA securities between the specified dates may have legal grounds to recover losses, depending on the outcomes of this class action. The deadline for filing as a lead plaintiff is approaching quickly; those interested must act by August 10, 2026. The ongoing situation highlights the importance of shareholder activism and the role of legal frameworks in safeguarding investor rights. By contacting Levi & Korsinsky LLP, affected shareholders can receive a thorough evaluation of their eligibility to participate in this collective legal action, which provides a means for them to seek redress without upfront fees.
For individuals or institutions who sold their ADMA shares at a loss during the class period, participation in the lawsuit remains an option, showcasing the court's recognition of losses incurred regardless of holding status. Levi & Korsinsky emphasizes that the complexities of securities law allow for multiple avenues of recovery for affected investors, reinforcing the necessity of gathering brokerage records and promptly initiating contact with legal counsel.
As this case unfolds, the significance of timely and accurate disclosures in the market will be under the microscope, with shareholders advocating for transparency and accountability. Those with questions about their potential participation in the class action are encouraged to promptly reach out to Levi & Korsinsky. The overarching message is clear: shareholders have rights, and taking action is crucial to safeguard those interests against corporate misconduct.
The controversy began when ADMA released its quarterly report for Q2 2024, where it disclosed purchases from GenesisBPS while neglecting to mention sales to Genesis BioPharma Services, an affiliated entity. This pattern of omission apparently continued in subsequent filings. Researchers have pointed out that while the company's reported revenues significantly surged from $92.6 million in 2023 to an impressive $362.5 million in 2025, these figures might have been artificially inflated due to a practice known as channel stuffing. Such a practice can significantly misrepresent a company’s financial health and mislead investors.
Culper Research, a company conducting independent investigations, published findings suggesting that ADMA’s reported growth was, in fact, a fabrication. They posited that absent channel stuffing, the revenue figures would illustrate a stark decline instead of the purported growth, raising substantial concerns about the accuracy of ADMA's financial statements. According to the allegations, the growth that ADMA claimed due to successful ASCENIV product sales was deceitful, with the real figures reflecting a 3% decline in revenues.
Investors who acquired shares of ADMA securities between the specified dates may have legal grounds to recover losses, depending on the outcomes of this class action. The deadline for filing as a lead plaintiff is approaching quickly; those interested must act by August 10, 2026. The ongoing situation highlights the importance of shareholder activism and the role of legal frameworks in safeguarding investor rights. By contacting Levi & Korsinsky LLP, affected shareholders can receive a thorough evaluation of their eligibility to participate in this collective legal action, which provides a means for them to seek redress without upfront fees.
For individuals or institutions who sold their ADMA shares at a loss during the class period, participation in the lawsuit remains an option, showcasing the court's recognition of losses incurred regardless of holding status. Levi & Korsinsky emphasizes that the complexities of securities law allow for multiple avenues of recovery for affected investors, reinforcing the necessity of gathering brokerage records and promptly initiating contact with legal counsel.
As this case unfolds, the significance of timely and accurate disclosures in the market will be under the microscope, with shareholders advocating for transparency and accountability. Those with questions about their potential participation in the class action are encouraged to promptly reach out to Levi & Korsinsky. The overarching message is clear: shareholders have rights, and taking action is crucial to safeguard those interests against corporate misconduct.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.